• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外药敏试验能否预测细菌性角膜炎的临床结局?

Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

作者信息

Chen Aiyin, Prajna Lalitha, Srinivasan Muthiah, Mahalakshmi Rajendran, Whitcher John P, McLeod Stephen, Lietman Thomas M, Acharya Nisha R

机构信息

F.I. Proctor Foundation, Department of Ophthalmology, University of California, San Francisco, San Francisco, California 94143, USA.

出版信息

Am J Ophthalmol. 2008 Mar;145(3):409-412. doi: 10.1016/j.ajo.2007.11.004. Epub 2008 Jan 22.

DOI:10.1016/j.ajo.2007.11.004
PMID:18207124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2267868/
Abstract

PURPOSE

To determine whether clinical outcomes in bacterial keratitis are associated with antibiotic susceptibility.

DESIGN

Retrospective, ancillary study using data and samples from a completed randomized clinical trial.

METHODS

Forty-two patients were enrolled with culture-confirmed bacterial keratitis at Aravind Eye Hospital in South India. All patients received topical moxifloxacin and were randomized to receive either topical prednisolone phosphate or placebo. Outcomes included time to epithelialization, best spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size at three months. Bacterial isolates were cultured, and minimum inhibitory concentration (MIC) to moxifloxacin was measured using Etests. Multiple linear regression was used to assess the effect of MIC on outcome, adjusting for enrollment characteristics.

RESULTS

MIC was associated with three-month infiltrate/scar size: each two-fold increase in MIC was associated with a 0.33-mm average diameter increase in scar size (P=.01). MIC was not associated with three-month BSCVA (P=.71) or time to epithelialization (P=.35).

CONCLUSIONS

MIC was associated with infiltrate/scar size in bacterial keratitis. An ongoing larger, multicenter trial should provide further information on whether this association is maintained across subgroups of organisms.

摘要

目的

确定细菌性角膜炎的临床结局是否与抗生素敏感性相关。

设计

采用来自一项已完成的随机临床试验的数据和样本进行回顾性辅助研究。

方法

印度南部阿拉文德眼科医院纳入了42例经培养确诊的细菌性角膜炎患者。所有患者均接受局部莫西沙星治疗,并随机分为接受局部磷酸泼尼松龙或安慰剂治疗。结局指标包括上皮化时间、最佳矫正视力(BSCVA)以及三个月时的浸润/瘢痕大小。对细菌分离株进行培养,并使用Etest测定对莫西沙星的最低抑菌浓度(MIC)。采用多元线性回归评估MIC对结局的影响,并对纳入特征进行校正。

结果

MIC与三个月时的浸润/瘢痕大小相关:MIC每增加两倍,瘢痕大小平均直径增加0.33 mm(P = 0.01)。MIC与三个月时的BSCVA(P = 0.71)或上皮化时间(P = 0.35)无关。

结论

MIC与细菌性角膜炎的浸润/瘢痕大小相关。一项正在进行的更大规模的多中心试验应能提供进一步信息,以确定这种关联在不同微生物亚组中是否依然存在。

相似文献

1
Does in vitro susceptibility predict clinical outcome in bacterial keratitis?体外药敏试验能否预测细菌性角膜炎的临床结局?
Am J Ophthalmol. 2008 Mar;145(3):409-412. doi: 10.1016/j.ajo.2007.11.004. Epub 2008 Jan 22.
2
Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).用于细菌性角膜炎的皮质类固醇:角膜溃疡类固醇试验(SCUT)。
Arch Ophthalmol. 2012 Feb;130(2):143-50. doi: 10.1001/archophthalmol.2011.315. Epub 2011 Oct 10.
3
Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis.莫西沙星药敏性介导了细菌性角膜炎的病原菌与临床结局之间的关系。
Invest Ophthalmol Vis Sci. 2013 Feb 28;54(2):1522-6. doi: 10.1167/iovs.12-11246.
4
Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis.体外对莫西沙星的敏感性与细菌性角膜炎的临床疗效的关系。
Clin Infect Dis. 2012 May;54(10):1381-7. doi: 10.1093/cid/cis189. Epub 2012 Mar 23.
5
Nocardia keratitis: clinical course and effect of corticosteroids.诺卡氏角膜炎:临床病程和皮质类固醇的作用。
Am J Ophthalmol. 2012 Dec;154(6):934-939.e1. doi: 10.1016/j.ajo.2012.06.001. Epub 2012 Sep 5.
6
The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.类固醇治疗角膜溃疡试验(SCUT):一项随机对照试验的次要 12 个月临床结局。
Am J Ophthalmol. 2014 Feb;157(2):327-333.e3. doi: 10.1016/j.ajo.2013.09.025. Epub 2013 Oct 1.
7
The steroids for corneal ulcers trial: study design and baseline characteristics.角膜溃疡类固醇试验:研究设计与基线特征
Arch Ophthalmol. 2012 Feb;130(2):151-7. doi: 10.1001/archophthalmol.2011.303. Epub 2011 Oct 10.
8
Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.绿脓杆菌角膜炎:结局和皮质类固醇治疗反应。
Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):267-72. doi: 10.1167/iovs.11-7840.
9
Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.氟喹诺酮类药物治疗与细菌性角膜炎分离株的敏感性。
JAMA Ophthalmol. 2013 Mar;131(3):310-3. doi: 10.1001/jamaophthalmol.2013.1718.
10
Moxifloxacin for bacterial keratitis.莫西沙星用于细菌性角膜炎。
Ophthalmology. 2008 Jun;115(6):1103; author reply 1103. doi: 10.1016/j.ophtha.2007.11.020.

引用本文的文献

1
Microbiological profiles of infectious corneal ulcers in Derbyshire and North Nottinghamshire-a 10-year analysis.德比郡和北诺丁汉郡感染性角膜溃疡的微生物学特征——一项为期10年的分析
Int Ophthalmol. 2025 Jan 31;45(1):58. doi: 10.1007/s10792-025-03432-6.
2
Topical blood products modulate the effects of ophthalmic antibiotics against common bacterial pathogens in dogs with infectious keratitis.局部应用血液制品可调节眼科抗生素对感染性角膜炎犬常见细菌病原体的作用。
Front Vet Sci. 2024 Jul 12;11:1417842. doi: 10.3389/fvets.2024.1417842. eCollection 2024.
3
Impact of multi-drug resistance on clinical outcomes of dogs with corneal ulcers infected with .多重耐药性对感染……的角膜溃疡犬临床结局的影响
Front Vet Sci. 2022 Nov 24;9:1083294. doi: 10.3389/fvets.2022.1083294. eCollection 2022.
4
Potential new fluoroquinolone treatments for suspected bacterial keratitis.疑似细菌性角膜炎的潜在新型氟喹诺酮类治疗方法。
BMJ Open Ophthalmol. 2022 Jul;7(1). doi: 10.1136/bmjophth-2022-001002.
5
Trends in the epidemiological and microbiological profiles of infectious keratitis in southeastern Brazil.巴西东南部感染性角膜炎的流行病学和微生物学特征趋势
Arq Bras Oftalmol. 2023 Jul-Aug;86(4):345-352. doi: 10.5935/0004-2749.20230050.
6
Albumin in Tears Modulates Bacterial Susceptibility to Topical Antibiotics in Ophthalmology.泪液中的白蛋白调节眼科局部抗生素对细菌的敏感性。
Front Med (Lausanne). 2021 Nov 30;8:663212. doi: 10.3389/fmed.2021.663212. eCollection 2021.
7
Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Ocular Infections.临床微生物学实验室实用指南:眼部感染的诊断。
Clin Microbiol Rev. 2021 Jun 16;34(3):e0007019. doi: 10.1128/CMR.00070-19. Epub 2021 Jun 2.
8
Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018.2009 年至 2018 年美国眼部微生物的抗生素耐药趋势。
JAMA Ophthalmol. 2020 May 1;138(5):439-450. doi: 10.1001/jamaophthalmol.2020.0155.
9
Microbial keratitis and the selection of topical antimicrobials.微生物性角膜炎与局部抗菌药物的选择
BMJ Open Ophthalmol. 2017 May 24;1(1):e000086. doi: 10.1136/bmjophth-2017-000086. eCollection 2017.
10
Cytotoxic clinical isolates of Pseudomonas aeruginosa identified during the Steroids for Corneal Ulcers Trial show elevated resistance to fluoroquinolones.在类固醇治疗角膜溃疡试验中鉴定出的具有细胞毒性的铜绿假单胞菌临床分离株对氟喹诺酮类药物的耐药性升高。
BMC Ophthalmol. 2014 Apr 24;14:54. doi: 10.1186/1471-2415-14-54.

本文引用的文献

1
Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).0.5%莫西沙星滴眼液(维加莫克斯)药效概述。
Surv Ophthalmol. 2005 Nov;50 Suppl 1:S7-15. doi: 10.1016/j.survophthal.2005.05.002.
2
In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.莫西沙星及0.5%莫西沙星滴眼液(一种新型局部用氟喹诺酮类药物)的体外和体内效力
Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. doi: 10.1016/j.survophthal.2005.06.002.
3
Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis.氟喹诺酮敏感性对氟喹诺酮治疗细菌性角膜炎疗效的影响。
Arch Ophthalmol. 2003 Sep;121(9):1229-33. doi: 10.1001/archopht.121.9.1229.
4
Corneal ulceration in the developing world--a silent epidemic.发展中世界的角膜溃疡——一种无声的流行病。
Br J Ophthalmol. 1997 Aug;81(8):622-3. doi: 10.1136/bjo.81.8.622.
5
The importance of initial management in the treatment of severe infectious corneal ulcers.初始管理在严重感染性角膜溃疡治疗中的重要性。
Ophthalmology. 1995 Dec;102(12):1943-8. doi: 10.1016/s0161-6420(95)30771-3.
6
Incidence of corneal ulceration in Madurai district, South India.印度南部马杜赖地区角膜溃疡的发病率。
Ophthalmic Epidemiol. 1996 Dec;3(3):159-66. doi: 10.3109/09286589609080122.
7
Incidence of ulcerative keratitis in a defined population from 1950 through 1988.1950年至1988年特定人群中溃疡性角膜炎的发病率。
Arch Ophthalmol. 1993 Dec;111(12):1665-71. doi: 10.1001/archopht.1993.01090120087027.
8
Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis.疱疹性眼病研究。口服阿昔洛韦治疗单纯疱疹性基质性角膜炎的对照试验。
Ophthalmology. 1994 Dec;101(12):1871-82. doi: 10.1016/s0161-6420(13)31155-5.
9
In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance.“试管内为真?”抗菌药物敏感性试验及其临床相关性。
J Infect Dis. 1981 Oct;144(4):380-5. doi: 10.1093/infdis/144.4.380.
10
Review of clinical experience with microbial keratitis associated with contact lenses.与隐形眼镜相关的微生物性角膜炎临床经验综述
CLAO J. 1987 Jul-Aug;13(4):211-4.